Atrium and Bristol-Myers Squibb received IND clearance from the FDA and obtained a No Objection Letter for Canadian sites.

The entities involved

• Atrium →
  • Partnership between Atrium and North Carolina State Health Plan adds 12 hospitals to the plan's Access level.Sat 05:21
• Bristol-Myers Squibb →

  American pharmaceutical company

  • Bristol-Myers Squibb is developing innovative treatments and supporting Cyprus' national effort in haematology.Mon 13:45
  • FDA gave tentative approval to Lupin for an alternative formulation of a Bristol-Myers Squibb drug, which Lupin plans to manufacture in Somerset.Mon 09:09
• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Related events

• FDA approval enables commercial opportunity involving CBRE Group.Sep 17
• The FDA upheld the De Novo denial for DrugSorb-ATR, a product of CytoSorbents. Phillip Chan serves as the company's CEO.Jun 7
• The FDA placed a clinical hold on the IND application for the company Aardvark.Jul 30
• AOTI Inc.'s therapy received regulatory clearance from the FDA, with the company based in Galway and Oceanside.Jun 19
• A study protocol involving a company based in Mont-Saint-Guibert was approved by the U.S. FDA.Sep 2